Biography

Iman Doostan, MD, PhD, is an Assistant Professor of Medicine in the Division of Hematology-Oncology at McGovern Medical School at UTHealth Houston. He received his medical degree from Isfahan University of Medical Sciences in Iran. He then moved to the United States, where he earned a Ph.D. in Cancer Biology from the University of Texas at Houston – MD Anderson Cancer Center. He subsequently completed his internal medicine residency at New York Medical College – Metropolitan Hospital, followed by a Hematology/Oncology Fellowship at UTHealth San Antonio- MD Anderson Cancer Center. He worked previously as an Assistant Professor of Medicine at the University of Miami-Sylvester Comprehensive Cancer Center in Florida.

Dr. Doostan’s primary area of care is breast oncology. He is board-certified by the American Board of Internal Medicine and the American Board of Medical Oncology.

His research focuses on clinical and translational studies aimed at identifying biomarkers of response and uncovering mechanisms of resistance to treatment in breast cancer. During his training, he received several honors, including the Oral Presentation Award in Translational Research and the CPRIT Graduate Scholar Award from MD Anderson Cancer Center, as well as the McDonald Award for Excellence in Cancer Research from UT San Antonio – MD Anderson Cancer Center.

 

Education

Medical School
Isfahan University of Medical Science, Isfahan, Iran
Residency
New York Medical College – Metropolitan Hospital, New York, NY
Fellowship
The University of Texas Health Science Center at San Antonio

Publications

Doostan I., Karakas C., Kohansal M., Low K.H., Ellis M.J., Olson J.A. Jr, Suman V.J., Hunt K.K., Moulder S.L., Keyomarsi K. Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer. Clin Cancer Res. 2017 Dec 1;23(23):7288-7300.

Bashour S.I., Doostan I., Keyomarsi K., Valero V., Ueno N.T., Brown P.H., Litton J.K., Koenig K.B., Karuturi M., Abouharb S., Tripathy D., Moulder-Thompson S.L., Ibrahim N.K. Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation. J Cancer. 2017 Jul 5;8(11):2004-2009.

Vijayaraghavan S., Karakas C., Doostan I., Chen X., Bui T., Yi M., Raghavendra A.S., Zhao Y., Bashour S.I., Ibrahim N.K., Karuturi M., Wang J., Winkler J.D., Amaravadi R.K., Hunt K.K., Tripathy D., Keyomarsi K. CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. Nat Commun. 2017 Jun 27;8:15916

Lucenay K.S., Doostan I., Karakas C., Bui T., Ding Z., Mills G.B., Hunt K.K., Keyomarsi K. Cyclin E Associates with the Lipogenic Enzyme ATP-Citrate Lyase to Enable Malignant Growth of Breast Cancer Cells. Cancer Res. 2016 Apr 15;76(8):2406-18

Kabiri Z., Salehi M., Mokarian F., Mohajeri M.R., Mahmoodi F., Keyhanian K., Doostan I., Ataollahi M.R., Modarressi M.H. Evaluation of ARG protein expression in mature B cell lymphomas compared to non-neoplastic reactive lymph node, Cell Immunol 2009 (259) 111-116.

Ataollahi M., Salehi M., Doostan I., et al. Bcl-2 associated athanogene-1 overexpression in diffuse large B-cell lymphoma, Iran J Immunol 2008 (5) 124-130.